June 23, 2026
Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Perseus Proteomics Signs Memorandum of Understanding with EirGenix to Explore Collaboration in Antibody Drugs

Perseus Proteomics Inc. hereby announces that it has entered into a memorandum of understanding with EirGenix, Inc., a Taiwan-based company, for the purpose of considering the possibility of collaboration in the research and development of antibody drugs, exploration of business opportunities, and related activities.

Based on this memorandum of understanding, the two companies will proceed with consideration, discussions, and evaluation regarding antibody research, collaboration related to contract development and manufacturing services, and mutual exploration of business opportunities. By leveraging the strengths of both companies and considering the possibility of collaboration related to the research, development, and manufacturing of antibody drugs, the companies will pursue the possibility of further business growth.

This memorandum of understanding is a non-binding agreement for the purpose of proceeding with such consideration, discussions, and evaluation, and does not constitute a commitment to enter into any specific or definitive transaction or collaboration at this time.

The signing of this memorandum of understanding is expected to have no impact on the Company's financial results at this time. The Company will promptly announce any matters requiring disclosure should they arise in the future.

Overview of EirGenix, Inc.

Location	No. 101, Lane 169, Kangning St., Xizhi Dist, New Taipei City 22180, Taiwan
Chairman and President	Lee-Cheng Liu
Established	December 2012
Business Description	Research and development of biopharmaceuticals and CDMO services